Patients with transfusion-dependent anemias are at risk for iron overload, a condition that can lead to serious complications, including organ failure and death.1-7 Recent research also indicates that patients with non-transfusion dependent thalassemia may also be at risk for this condition.8 Iron chelation therapy can reduce iron levels in these patients, and adherence is critical to treatment success.8,9 This section discusses patient adherence and some consequences of iron overload, which may result from non-adherence, in addition to treatment guidelines.1-9
All fields are required.
You are now leaving the IronHealthalliance.com website by opening an external website independently operated and not managed by Novartis. Novartis assumes no responsibility for the site you are about to visit. If you do not wish to leave this site, click "Cancel." Otherwise, click "Continue".